Ampyra Approval: Acorda's Lessons Learned
This article was originally published in Pharmaceutical Approvals Monthly
There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.
You may also be interested in...
Congenial Acorda CEO Ron Cohen is chosen to lead the industry group during the upcoming year as the biotech industry gathers in Philadelphia for BIO's annual conference.